Understanding the Metformin in Longevity Study (MILES Trial)

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

The MILES Trial (NCT02432287) stands as a crucial early step in understanding metformin’s potential beyond diabetes. While the larger, more ambitious TAME (Targeting Aging with Metformin) Trial aims to prove metformin’s ability to prevent age-related diseases, MILES was a pilot study designed to delve into the fundamental biological changes metformin might induce in healthy older adults.

# Understanding the Metformin in Longevity Study (MILES Trial)

In the burgeoning field of longevity research, the Metformin in Longevity Study, or MILES Trial (NCT02432287), stands as a crucial early step in understanding metformin’s potential beyond diabetes. While the larger, more ambitious TAME (Targeting Aging with Metformin) Trial aims to prove metformin’s ability to prevent age-related diseases, MILES was a pilot study designed to delve into the fundamental biological changes metformin might induce in healthy older adults. If you’re tracking the scientific journey of metformin as a geroprotector, understanding MILES is essential.

MILES: A Deep Dive into the Biology of Aging

The MILES Trial was conceived as a pilot study to investigate whether metformin could influence the biology of aging at a molecular level in humans. The researchers aimed to determine if metformin treatment could restore gene expression patterns in older individuals to resemble those of younger individuals, essentially looking for molecular markers of rejuvenation [1].

Unlike TAME, which focuses on clinical outcomes (disease incidence), MILES focused on biomarkers of aging. These are measurable biological characteristics that change with age and are thought to reflect the underlying aging process. Examples include changes in gene expression, inflammation markers, and mitochondrial function.

Study Design and Key Findings

The MILES trial was a randomized, double-blind, placebo-controlled pilot study. It enrolled healthy older adults (aged 60-75) who were not diabetic. Participants received either metformin or a placebo for a period of six months. The researchers then analyzed various biological samples (e.g., blood, muscle biopsies) to look for changes in aging biomarkers.

Preliminary analysis of the MILES trial results indicated that metformin did induce anti-aging transcriptional changes. Specifically, it appeared to restore certain gene expression patterns in muscle tissue that are associated with younger individuals. This suggests that metformin might indeed be capable of modulating fundamental biological processes related to aging in humans, even in non-diabetic individuals [2].

While these findings were preliminary and from a small pilot study, they provided crucial proof-of-concept. They demonstrated that metformin could have a measurable impact on the biology of aging in humans, laying the groundwork for larger, outcome-based trials like TAME.

MILES vs. TAME: Complementary Approaches

It’s important not to confuse MILES with TAME. They serve different, but complementary, purposes:

MILES (Metformin in Longevity Study): A pilot study focused on mechanistic insights and biomarkers of aging in healthy older adults. Its goal was to see if metformin could induce molecular changes associated with anti-aging.

TAME (Targeting Aging with Metformin): A large-scale, phase 3 clinical trial focused on clinical outcomes (delaying age-related diseases) in older adults at risk for these diseases. Its goal is to prove that metformin can extend healthy human lifespan by preventing multiple diseases simultaneously.

MILES provided the initial human evidence that metformin could affect the biology of aging, giving further impetus and scientific justification for the much larger and more expensive TAME trial. Without studies like MILES, it would be much harder to justify the investment in trials like TAME.

Practical Takeaway

The MILES Trial, though a pilot study, was a significant milestone in human longevity research. It provided early evidence that metformin can induce molecular changes in healthy older adults consistent with an anti-aging effect. This doesn’t mean metformin is a proven longevity drug yet, but it strongly supports the hypothesis that targeting aging is possible and that metformin is a promising candidate. For those interested in the scientific progression of geroprotectors, MILES demonstrated that metformin’s effects extend beyond glucose control to the very biology of aging. It underscores the importance of ongoing research to translate animal findings into safe and effective human interventions.

---

References

[1] ClinicalTrials.gov: Metformin in Longevity Study (MILES) (https://clinicaltrials.gov/study/NCT02432287)

[2] Frontiers in Endocrinology: A Critical Review of the Evidence That Metformin Is a Putative Anti... (https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.718942/full)